1
|
Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol 2018; 11:96. [PMID: 30041662 PMCID: PMC6057006 DOI: 10.1186/s13045-018-0639-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 07/09/2018] [Indexed: 01/14/2023] Open
Abstract
Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.
Collapse
Affiliation(s)
- E Genescà
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain. .,ALL Research Group, Josep Carreras Leukaemia Research Institute (IJC), Camí de les Escoles s/n. Edifici IJC, 08916, Badalona, Spain.
| | - A Lazarenkov
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - M Morgades
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - G Berbis
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - N Ruíz-Xivillé
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - P Gómez-Marzo
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - J Ribera
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - J Juncà
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - A González-Pérez
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain
| | - S Mercadal
- Clinical Hematology Service, Hospital Duran i Reynals-ICO, Hospitalet del LLobregat, Barcelona, Spain
| | - R Guardia
- Clinical Hematology Service, Hospital Josep Trueta-ICO, Girona, Spain
| | - M T Artola
- Clinical Hematology Service, Hospital Universitario de Donostia, Donostia, Spain
| | - M J Moreno
- Clinical Hematology Service, Hospital Vírgen de la Victoria, Málaga, Spain
| | - J Martínez-López
- Hematology Department, Hospital 12 de Octubre, CNIO, Universidad Complutense, Madrid, Spain
| | - L Zamora
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - P Barba
- Clinical Hematology Service, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain
| | - C Gil
- Clinical Hematology Service, Hospital General de Alicante, Alicante, Spain
| | - M Tormo
- Clinical Hematology Service, Hospital Clínico de Valencia, Valencia, Spain
| | - A Cladera
- Clinical Hematology Service, Hospital Son Llàtzer, Palma, Spain
| | - A Novo
- Clinical Hematology Service, Hospital Son Espases, Palma, Spain
| | - M Pratcorona
- Clinical Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J Nomdedeu
- Clinical Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J González-Campos
- Clinical Hematology Service, Hospital Vírgen del Rocío, Sevilla, Spain
| | - M Almeida
- Banco Nacional de ADN Carlos III, Universidad de Salamanca, Salamanca, Spain
| | - J Cervera
- Biobanco de la Fe, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain
| | - P Montesinos
- Clinical Hematology Service, Hospital La Fe, Valencia, Spain
| | - M Batlle
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - S Vives
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - J Esteve
- Clinical Hematology Service, Hospital Clínic de Barcelona, Barcelona, Spain
| | - E Feliu
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - F Solé
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - A Orfao
- Centro de Investigación del Cáncer (IBMCC-CSIC/USAL) (CIC), Hospital Clínico Universitario de Salamanca (HUS), Instituto Bio-Sanitario de Salamanca (IBSAL), CIBERONC, Salamanca, Spain
| | - J M Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| |
Collapse
|
2
|
Hurtado A, Luengo-Gil G, Chen-Liang T, Palomo L, Lumbreras E, Przychodzen B, Amigo M, Díez-Campelo M, Zamora L, Ortuño F, Vicente V, Maciejewski J, del Cañizo C, Solé F, Ferrer-Marín F, Jerez A. DNA Repair Genes Transcriptome in Chronic Myelomonocytic Leukemia. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30276-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Palomo L, Ibáñez M, Abáigar M, Vázquez I, Álvarez S, Cabezón M, Tazón-Vega B, Acha P, Benito R, Cervera J, Cigudosa J, Fuster-Tormo F, Hernández Sánchez J, Larrayoz M, Valcárcel D, Zamora L, Sanz G, Calasanz M, Solé F, Such E. Spanish Guidelines for the use of Targeted Deep Sequencing in MDS and CMML. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30139-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Palomo L, Malinverni R, Cabezón M, Xicoy B, Arnan M, Coll R, Pomares H, Grau J, Navarro T, Feliu E, Solé F, Buschbeck M, Zamora L. DNA Methylation Profiling in Patients with CMML Differs Between Normal and Altered Karyotype. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30261-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Nomdedeu M, Tuechler H, Kuendgen A, Solé F, Schanz J, Hildebrandt B, Grau J, Pereira A, García-Manero G, Sekeres M, Komrokji R, Voso M, List A, Cazzola M, Sill H, Stauder R, Greenberg P, Germing U, Sanz G, Haase D. Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30161-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Liquori A, Such E, Palomo L, Moreau S, Pedrola L, Sellés J, Neef A, Zúñiga S, Ibáñez M, Company D, Saus A, Acha P, Sanjuan-Pla A, Boluda M, de Matteo B, González E, Sanz M, Solé F, Sanz G, Cervera J. A Single Next-Generation Sequencing (NGS) Assay for the Detection of Point Mutations and Large Chromosomal Abnormalities in MDS Patients. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30143-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia 2015; 29:1502-13. [PMID: 25721895 DOI: 10.1038/leu.2015.55] [Citation(s) in RCA: 89] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2015] [Revised: 02/10/2015] [Accepted: 02/16/2015] [Indexed: 02/03/2023]
Abstract
A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based Prognostic Scoring System (WPSS) by determining the impact of the newer clinical and cytogenetic features, and we compared its prognostic power to that of the revised International Prognostic Scoring System (IPSS-R). A population of 5326 untreated MDS was considered. We analyzed single WPSS parameters and confirmed that the WHO classification and severe anemia provide important prognostic information in MDS. A strong correlation was found between the WPSS including the new cytogenetic risk stratification and WPSS adopting original criteria. We then compared WPSS with the IPSS-R prognostic system. A highly significant correlation was found between the WPSS and IPSS-R risk classifications. Discrepancies did occur among lower-risk patients in whom the number of dysplastic hematopoietic lineages as assessed by morphology did not reflect the severity of peripheral blood cytopenias and/or increased marrow blast count. Moreover, severe anemia has higher prognostic weight in the WPSS versus IPSS-R model. Overall, both systems well represent the prognostic risk of MDS patients defined by WHO morphologic criteria. This study provides relevant in formation for the implementation of risk-adapted strategies in MDS.
Collapse
Affiliation(s)
- M G Della Porta
- 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Internal Medicine, University of Pavia, Pavia, Italy
| | - H Tuechler
- Hanusch Hospital, Boltzmann Institute for Leukemia Research, Vienna, Austria
| | - L Malcovati
- 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - J Schanz
- Georg August Universität, Göttingen, Germany
| | - G Sanz
- Hospital Universitario La Fe, Valencia, Spain
| | - G Garcia-Manero
- The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - F Solé
- Institut de Recerca contra la Leucèmia Josep Carreras, Barcelona, Spain
| | - J M Bennett
- James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
| | - D Bowen
- St James's University Hospital, Leeds, UK
| | - P Fenaux
- Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP)/University Paris XIII, Bobigny, France
| | - F Dreyfus
- Hôpital Cochin, AP-HP University of Paris V, Paris, France
| | - H Kantarjian
- The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - A Kuendgen
- Heinrich-Heine University Hospital, Düsseldorf, Germany
| | - A Levis
- Fondazione Italiana Sindromi Mielodisplastiche c/o SS Antonio e Biagio Hospital, Alessandria, Italy
| | - J Cermak
- Institute of Hematology and Blood Transfusion, Praha, Czech Republic
| | - C Fonatsch
- Medical University of Vienna, Vienna, Austria
| | - M M Le Beau
- University of Chicago Comprehensive Cancer Research Center, Chicago, IL, USA
| | - M L Slovak
- Quest Diagnostics Nichols Institute, Chantilly, VA, USA
| | - O Krieger
- Elisabethinen Hospital, Linz, Austria
| | - M Luebbert
- University of Freiburg Medical Center, Freiburg, Germany
| | | | | | - Y Miyazaki
- Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - M Pfeilstöcker
- Hanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria
| | | | - W R Sperr
- Medical University of Vienna, Vienna, Austria
| | - R Stauder
- Hanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria
| | - S Tauro
- University of Dundee, Dundee, Scotland, UK
| | - P Valent
- Medical University of Vienna, Vienna, Austria
| | - T Vallespi
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | | | - U Germing
- Heinrich-Heine University Hospital, Düsseldorf, Germany
| | - D Haase
- Georg August Universität, Göttingen, Germany
| | - P L Greenberg
- Division of Hematology, Stanford University Cancer Center, Stanford, CA, USA
| | - M Cazzola
- 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Molecular Medicine, University of Pavia, Pavia, Italy
| |
Collapse
|
8
|
McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J 2015; 5:e291. [PMID: 25768405 PMCID: PMC4382654 DOI: 10.1038/bcj.2015.11] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 01/13/2015] [Indexed: 01/22/2023] Open
Abstract
Nonsynonymous TP53 exon 4 single-nucleotide polymorphism (SNP), R72P, is linked to cancer and mutagen susceptibility. R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting. Myelodysplastic syndrome (MDS) with chromosome 5q deletion is characterized by erythroid hypoplasia arising from lineage-specific p53 accumulation resulting from ribosomal insufficiency. We hypothesized that apoptotically diminished R72P C-allele may influence predisposition to del(5q) MDS. Bone marrow and blood DNA was sequenced from 705 MDS cases (333 del(5q), 372 non-del(5q)) and 157 controls. Genotype distribution did not significantly differ between del(5q) cases (12.6% CC, 38.1% CG, 49.2% GG), non-del(5q) cases (9.7% CC, 44.6% CG, 45.7% GG) and controls (7.6% CC, 37.6% CG, 54.8% GG) (P=0.13). Allele frequency did not differ between non-del(5q) and del(5q) cases (P=0.91) but trended towards increased C-allele frequency comparing non-del(5q) (P=0.08) and del(5q) (P=0.10) cases with controls. Median lenalidomide response duration increased proportionate to C-allele dosage in del(5q) patients (2.2 (CC), 1.3 (CG) and 0.89 years (GG)). Furthermore, C-allele homozygosity in del(5q) was associated with prolonged overall and progression-free survival and non-terminal interstitial deletions that excluded 5q34, whereas G-allele homozygozity was associated with inferior outcome and terminal deletions involving 5q34 (P=0.05). These findings comprise the largest MDS R72P SNP analysis.
Collapse
Affiliation(s)
- K L McGraw
- Hematology Department, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | - L M Zhang
- Molecular Genomics Core Lab, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | - D E Rollison
- Cancer Epidemiology, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | - A A Basiorka
- 1] Hematology Department, H Lee Moffitt Cancer Center, Tampa, FL, USA [2] Cancer Biology PhD Program, University of South Florida, Tampa, FL, USA
| | - W Fulp
- Biostatistics and Bioinformatics Department, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | - B Rawal
- Mayo Clinic, Biostatistics-Division of Health Sciences Research, Jacksonville, FL, USA
| | - A Jerez
- Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA
| | | | - H-Y Lin
- Biostatistics and Bioinformatics Department, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | | | - S Yoder
- Molecular Genomics Core Lab, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | - Y Zhang
- Biostatistics and Bioinformatics Department, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | - K Guinta
- Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA
| | - M Mallo
- Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) Badalona, Barcelona, Spain
| | - F Solé
- Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) Badalona, Barcelona, Spain
| | - M J Calasanz
- Hematology Department, Hospital Universitario La Fe, Valencia, Spain
| | - J Cervera
- Hematology Department, Hospital Universitario La Fe, Valencia, Spain
| | - E Such
- Hematology Department, Hospital Universitario La Fe, Valencia, Spain
| | - T González
- Genomics Medicine Public Foundation, Hospital Clinico Universitario, Santiago de Compostela, Spain
| | - T J Nevill
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | | | - A E Smith
- King's College London, King's College Hospital, London, UK
| | | | - G Mufti
- King's College London, King's College Hospital, London, UK
| | - A Karsan
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | - J P Maciejewski
- Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA
| | - L Sokol
- Hematology Department, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | | | - S Wei
- Immunology Department, H Lee Moffitt Cancer Center, Tampa, FL, USA
| | - A F List
- Hematology Department, H Lee Moffitt Cancer Center, Tampa, FL, USA
| |
Collapse
|
9
|
Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 2013; 27:1988-95. [PMID: 23787396 DOI: 10.1038/leu.2013.187] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Revised: 05/30/2013] [Accepted: 06/04/2013] [Indexed: 11/09/2022]
Abstract
Monosomal karyotype (MK) is associated with an adverse prognosis in patients in acute myeloid leukemia (AML). This study analyzes the prognostic impact of MK in a cohort of primary, untreated patients with myelodysplastic syndromes (MDS). A total of 431 patients were extracted from an international database. To analyze whether MK is an independent prognostic marker in MDS, cytogenetic and clinical data were explored in uni- and multivariate models regarding overall survival (OS) as well as AML-free survival. In all, 204/431 (47.3%) patients with MK were identified. Regarding OS, MK was prognostically significant in patients with ≤ 4 abnormalities only. In highly complex karyotypes (≥ 5 abnormalities), MK did not separate prognostic subgroups (median OS 4.9 months in MK+ vs 5.6 months in patients without MK, P=0.832). Based on the number of abnormalities, MK-positive karyotypes (MK+) split into different prognostic subgroups (MK+ and 2 abnormalities: OS 13.4 months, MK+ and 3 abnormalities: 8.0 months, MK+ and 4 abnormalities: 7.9 months and MK+ and ≥ 5 abnormalities: 4.9 months; P<0.01). In multivariate analyses, MK was not an independent prognostic factor. Our data support the hypothesis that a high number of complex abnormalities, associated with an instable clone, define the subgroup with the worst prognosis in MDS, independent of MK.
Collapse
Affiliation(s)
- J Schanz
- Department of Hematology and Oncology, University of Göttingen, Göttingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Cigudosa J, Ibañez M, Mallo M, Such E, Larrayoz M, Cervera J, Solé F, Calasanz M, Hernández-Rivas J, Álvarez S. P-017 Genetic alterations of the epigenetic pathways on MDS patients with a 5q deletion drive specific methylation signatures. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70066-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Palomo L, Mallo M, Xicoy B, Ademà V, Garcia O, Marcé S, Grau J, Jiménez M, Alonso E, Pomares H, Arnan M, Arenillas L, Florensa L, Ayats J, Lemes A, Millá F, Feliu E, Solé F, Zamora L. P-069 Contribution of SNP-arrays and mutational studies to diagnosis and prognosis of CMML with low-risk cytogenetic features or no metaphases. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70118-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Saumell S, Solé F, Arenillas L, Montoro J, Valcárcel D, Pedro C, Sanzo C, Luño E, Giménez T, Arnan M, Pomares H, De Paz R, Arrizabalaga B, Jerez A, Martínez A, Sánchez-Castro J, Rodríguez J, Raya J, Ríos E, Rodríguez M, Espinet B, Lourdes F. P-068 Trisomy 8 in de novo MDS, constitutional or not constitutional? Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70117-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Cooper H, Solé P, Solé F, Robano A, Zivov A, Campos P. Systemic inflammatory response syndrome in orthognathic surgery. Int J Oral Maxillofac Surg 2011. [DOI: 10.1016/j.ijom.2011.07.542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Serrano MJ, Nadal R, Lorente JA, Salido M, Rodríguez R, Rodríguez M, Macià M, Sánchez-Rovira P, Corominas JM, González L, Vera L, Albanell J, Solé F. Circulating cancer cells in division in an early breast cancer patient. Ann Oncol 2011; 22:2150-2151. [PMID: 21743104 DOI: 10.1093/annonc/mdr322] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Affiliation(s)
- M J Serrano
- Pfizer-University of Granada-Andalusian Government Center of Genomics and Oncology (GENyO), Granada.
| | - R Nadal
- Molecular Cytogenetics Laboratory, Pathology Department, Parc de Salut Mar-Hospital del Mar, IMIM-GRETNHE, Barcelona
| | - J A Lorente
- Pfizer-University of Granada-Andalusian Government Center of Genomics and Oncology (GENyO), Granada; Laboratory of Genetic Identification-UGR, Department of Legal Medicine, University of Granada, Granada
| | - M Salido
- Molecular Cytogenetics Laboratory, Pathology Department, Parc de Salut Mar-Hospital del Mar, IMIM-GRETNHE, Barcelona
| | - R Rodríguez
- Laboratory of Genetic Identification, Department of Legal Medicine, University of Granada, Granada
| | - M Rodríguez
- Molecular Cytogenetics Laboratory, Pathology Department, Parc de Salut Mar-Hospital del Mar, IMIM-GRETNHE, Barcelona
| | - M Macià
- Oncology Department, Hospital del Mar-IMAS, Barcelona
| | - P Sánchez-Rovira
- Pfizer-University of Granada-Andalusian Government Center of Genomics and Oncology (GENyO), Granada; Medical Oncology Department, University Hospital, Jaén, Spain
| | - J M Corominas
- Molecular Cytogenetics Laboratory, Pathology Department, Parc de Salut Mar-Hospital del Mar, IMIM-GRETNHE, Barcelona
| | - L González
- Pfizer-University of Granada-Andalusian Government Center of Genomics and Oncology (GENyO), Granada
| | - L Vera
- Pfizer-University of Granada-Andalusian Government Center of Genomics and Oncology (GENyO), Granada
| | - J Albanell
- Oncology Department, Hospital del Mar-IMAS, Barcelona
| | - F Solé
- Molecular Cytogenetics Laboratory, Pathology Department, Parc de Salut Mar-Hospital del Mar, IMIM-GRETNHE, Barcelona
| |
Collapse
|
15
|
Martín-Ezquerra G, Salgado R, Toll A, Gilaberte M, Baró T, Alameda Quitllet F, Yébenes M, Solé F, Garcia-Muret M, Espinet B, Pujol R. Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC
, TP53
, CCDN1, EGFR
and ERBB2
status in primary and metastatic tumours. Br J Dermatol 2010; 163:1028-35. [DOI: 10.1111/j.1365-2133.2010.09947.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Toll A, Salgado R, Yébenes M, Martín-Ezquerra G, Gilaberte M, Baró T, Solé F, Alameda F, Espinet B, Pujol R. MYCgene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol 2009; 161:1112-8. [DOI: 10.1111/j.1365-2133.2009.09351.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
17
|
Mallo M, Cervera J, Schanz J, Espinet B, Duch E, Luño E, Steidl C, Martín M, Germing U, Grau J, Pfeilstoecker M, Hernández-Rivas J, Noesslinger T, Calasanz M, Collado R, Fonatsch C, Bureo E, Lübbert M, Ríos R, Stauder R, Arranz E, Hildebrandt B, Slovak M, Cigudosa J, Krieger O, Pedro C, Salido M, Arenillas L, Sanz G, Sanz M, Valencia A, Florensa L, Novell L, del Cañizo C, García-Manero G, Vallespí T, Ohyashiki K, Benlloch L, Haase D, Solé F. C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70043-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Such E, Cervera J, Costa D, Solé F, Luño E, Nomdedeu B, Vallespí T, Carbonell F, Ardanaz M, Ramos F, Tormo M, del Cañizo C, Mallo M, Xicoy B, Gomez V, Marco V, Bonanad S, Collado R, Calasanz M, Cruz-Cigudosa J, Hernández-Rivas J, Senent M, Pedro C, Bernal T, Bueno J, Sanz G. P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70109-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Salgado R, Toll A, Espinet B, González-Roca E, Barranco CL, Serrano S, Solé F, Pujol RM. [Analysis of cytogenetic abnormalities in squamous cell carcinoma by array comparative genomic hybridization]. Actas Dermosifiliogr 2008; 99:199-206. [PMID: 18358195 DOI: 10.1016/s1578-2190(08)70232-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
INTRODUCTION Few conventional cytogenetic studies of squamous cell carcinoma (SCC) have been performed to date. The introduction of cytogenetic techniques such as comparative genomic hybridization (CGH) has resolved some of the problems associated with conventional cytogenetics. The aim of this study was to analyze the presence of genetic abnormalities in a series of patients with SCC using the technique of array CGH. MATERIAL AND METHODS The study included 8 patients (7 men and 1 woman; mean age, 75 years) diagnosed with primary SCC. DNA was extracted from frozen tissue and analyzed by array CGH. RESULTS All cases had genetic alterations, with gains more frequent than losses. The chromosomal regions with gains, in descending order of frequency, were as follows: 5p15.2, 9q31.3-q33.2, 13q, 18q22, 1p21-p22, 1q24-q25, 3p13, 4q33-q34 (HMGB2, SAP30), 20p12.2 (JAG1), 21q21.1, and Xq21.33. The region 9p13.1-p13.3 was the only one to display recurrent loss. No correlation was observed between the presence of gains or losses and the clinical and pathological characteristics of the tumors. CONCLUSIONS This is the first study to use the technique of array CGH to analyze genetic alterations in SCC. The finding of certain previously described aberrations (gain of 5p) suggests the existence of recurrent abnormalities. Likewise, the observation of alterations in small regions of chromosome 1 highlights the sensitivity of the technique to detect small changes. Application of the technique to a larger series of cases will provide greater insight into the genetic abnormalities implicated in the process of tumorigenesis in SCC.
Collapse
Affiliation(s)
- R Salgado
- Servicio de Anatomía Patológica. Laboratorio de Citogenética y Biología Molecular. Hospital del Mar. Barcelona. España
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Puigdecanet E, Espinet B, Lozano JJ, Sumoy L, Bellosillo B, Arenillas L, Alvarez-Larrán A, Solé F, Serrano S, Besses C, Florensa L. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. Leukemia 2008; 22:1368-76. [PMID: 18480837 DOI: 10.1038/leu.2008.112] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
To explore the gene expression signature in essential thrombocythemia (ET) patients in relation to JAK2V617F mutational status, expression profiling in circulating granulocytes was performed. Twenty ET were studied by microarray analysis and the results were confirmed by real-time quantitative RT-PCR in 40 ET patients, not receiving cytoreductive treatment. A heterogeneous molecular signature characterized by two main gene expression patterns was found: one with an upregulation of inflammatory genes related to neutrophil activation and thrombosis, and the other with significantly lower expression of these genes. Supervised clustering analysis showed 30 genes differentially expressed between JAK2V617F-negative and JAK2V617F-positive ET patients. Among the JAK2V617F-negative, a set of 14 genes (CISH, C13orf18, CCL3, PIM1, MAFF, SOCS3, ID2, GADD45B, KLF5, TNF, LAMB3, HRH4, TAGAP and TRIB1) showed an abnormal expression pattern. In this group of patients, CISH, SOCS2, SOCS3 and PIM1 genes, all involved in JAK-STAT signalling pathway, presented a lower expression. A two-gene predictor model was built comprising FOSB and CISH genes, which were the best discriminators of JAK2V617F status. In conclusion, JAK2V617F-negative ET patients present a characteristic gene expression profile, different from JAK2V617F-positive patients. Other pathways, besides JAK-STAT, might be implicated in the pathophysiology of JAK2V617F-negative ET patients.
Collapse
Affiliation(s)
- E Puigdecanet
- Laboratori de Citogenètica i Biologia Molecular, Servei de Patologia. Hospital del Mar, IMAS, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Salgado R, Toll A, Espinet B, González-Roca E, Barranco C, Serrano S, Solé F, Pujol R. Estudio de las lesiones citogenéticas en el carcinoma escamoso cutáneo mediante la técnica de arrays de hibridación genómica comparada. Actas Dermo-Sifiliográficas 2008. [DOI: 10.1016/s0001-7310(08)74656-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
22
|
Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2007; 22:487-95. [PMID: 18094718 DOI: 10.1038/sj.leu.2405068] [Citation(s) in RCA: 204] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.
Collapse
Affiliation(s)
- E Matutes
- Section of Haemato-Oncology, Institute of Cancer Research, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Coccé MC, Villa O, Obregon MG, Salido M, Barreiro C, Solé F, Gallego MS. Duplication dup(1)(q41q44) defined by fluorescence in situ hybridization: delineation of the ‘trisomy 1q42→qter syndrome’. Cytogenet Genome Res 2007; 118:84-6. [PMID: 17901705 DOI: 10.1159/000106446] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2006] [Accepted: 03/07/2007] [Indexed: 11/19/2022] Open
Abstract
We report on a novel case of pure partial tandem duplication 1q42q43 confirmed by fluorescence in situ hybridization (FISH). We compare the manifestations of our patient with similar cases previously reported. We conclude that the most common clinical manifestations of trisomy 1q42qter are prenatal and postnatal growth retardation, relative macrocephaly, triangular face, prominent forehead, broad nasal bridge, abnormal philtrum, micro/retrognathia, cardiac defects and mental retardation. We would like to emphasize the importance of the FISH technique in the identification of the duplicated segment.
Collapse
Affiliation(s)
- M C Coccé
- Laboratorio de Citogenética, Servicio de Genética, Hospital de Pediatría Prof. Dr. J.P. Garrahan, Buenos Aires, Argentina.
| | | | | | | | | | | | | |
Collapse
|
24
|
Martín-Subero JI, Ibbotson R, Klapper W, Michaux L, Callet-Bauchu E, Berger F, Calasanz MJ, De Wolf-Peeters C, Dyer MJ, Felman P, Gardiner A, Gascoyne RD, Gesk S, Harder L, Horsman DE, Kneba M, Küppers R, Majid A, Parry-Jones N, Ritgen M, Salido M, Solé F, Thiel G, Wacker HH, Oscier D, Wlodarska I, Siebert R. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. Leukemia 2007; 21:1532-44. [PMID: 17495977 DOI: 10.1038/sj.leu.2404695] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The biologic and pathologic features of B-cell malignancies bearing a translocation t(14;19)(q32;q13) leading to a fusion of IGH and BCL3 are still poorly described. Herein we report the results of a comprehensive cytogenetic, fluorescence in situ hybridization (FISH), molecular and histopathological survey of a large series of B-cell malignancies with t(14;19) or variant translocations. A total of 56 B-cell malignancies with a FISH-proven BCL3 involvement were identified with the translocation partners being IGH (n=51), IGL (n=2), IGK (n=2) and a non-IG locus (n=1). Hierarchical clustering of chromosomal changes associated with the t(14;19) indicated the presence of two different groups of IG/BCL3-positive lymphatic neoplasias. The first group included 26 B-cell malignancies of various histologic subtypes containing a relatively high number of chromosomal changes and mostly mutated IgVH genes. This cluster displayed three cytogenetic branches, one with rearrangements in 7q, another with deletions in 17p and a third one with rearrangements in 1q and deletions in 6q and 13q. The second group included 19 cases, mostly diagnosed as B-cell chronic lymphocytic leukemia (B-CLL), and characterized by few additional chromosomal changes (e.g. trisomy 12) and unmutated IgVH genes. In conclusion, our study indicates that BCL3 translocations are not restricted to B-CLL but present in a heterogeneous group of B-cell malignancies.
Collapse
MESH Headings
- Adult
- Aged
- B-Cell Lymphoma 3 Protein
- Chromosomes, Human, Pair 14
- Chromosomes, Human, Pair 19
- Cytogenetic Analysis
- Female
- Gene Rearrangement
- Genes, Immunoglobulin
- Histocytochemistry
- Humans
- In Situ Hybridization, Fluorescence
- Leukemia, B-Cell/classification
- Leukemia, B-Cell/genetics
- Leukemia, B-Cell/pathology
- Lymphoma, B-Cell/classification
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/pathology
- Male
- Middle Aged
- Proto-Oncogene Proteins/genetics
- Transcription Factors/genetics
- Translocation, Genetic
Collapse
Affiliation(s)
- J I Martín-Subero
- Institute of Human Genetics, University Hospital Schleswig-Holstein Campus Kiel, Christian-Albrechts University, Kiel, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Bellosillo B, Martínez-Avilés L, Gimeno E, Florensa L, Longarón R, Navarro G, Salar A, Espinet B, Solé F, Serrano S, Besses C. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia 2007; 21:1331-2. [PMID: 17361221 DOI: 10.1038/sj.leu.2404649] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
26
|
Florensa L, Bellosillo B, Besses C, Puigdecanet E, Espinet B, Pérez-Vila E, Longarón R, Vilà RM, Solé F, Serrano S. JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients. Leukemia 2006; 20:1903-5. [PMID: 16888614 DOI: 10.1038/sj.leu.2404341] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
27
|
Bellosillo B, Besses C, Florensa L, Solé F, Serrano S. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders. Leukemia 2006; 20:736-7. [PMID: 16453004 DOI: 10.1038/sj.leu.2404123] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
28
|
Lloveras E, Pérez C, Solé F, Zamora L, Lladonosa A, Espinet B, Silvestre E, Serra J, Vendrell T, Fernández B, Salido M, Plaja A. Two cases of tetrasomy 9p syndrome with tissue limited mosaicism. Am J Med Genet A 2004; 124A:402-6. [PMID: 14735590 DOI: 10.1002/ajmg.a.20447] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Tetrasomy of short arm of chromosome 9 constitutes a clinically recognizable chromosomal syndrome. Isochromosome 9p shows a strong propensity to tissue-limited mosaicism. It occurs predominantly in peripheral blood cultures, often at a lower frequency or even absent in skin, amniotic fluid or chorionic villous cell cultures. Tissue-limited nature of mosaicism may render prenatal detection of this condition very difficult. Herein, we report two new cases of mosaic tetrasomy 9p. Conventional cytogenetics (CC) and FISH studies demonstrated a differential expression of the mosaicism in several tissues. We review the literature and discuss the implications of these findings in cytogenetic prenatal diagnosis.
Collapse
Affiliation(s)
- Elisabet Lloveras
- Departament de Citogenética, General Lab-Laboratoris d'Anàlisis, C/Londres no. 45, 08036 Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Florensa L, Zamora L, Besses C, Ortega JJ, Bastida P, Toll T, Mayayo P, Espinet B, Solé F, Serrano S, Woessner S. Cultures of myeloid progenitor cells in pediatric essential thrombocythemia. Leukemia 2002; 16:1876-7. [PMID: 12200712 DOI: 10.1038/sj.leu.2402574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2002] [Accepted: 03/28/2002] [Indexed: 11/08/2022]
|
30
|
Sonoki T, Harder L, Horsman DE, Karran L, Taniguchi I, Willis TG, Gesk S, Steinemann D, Zucca E, Schlegelberger B, Solé F, Mungall AJ, Gascoyne RD, Siebert R, Dyer MJ. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood 2001; 98:2837-44. [PMID: 11675358 DOI: 10.1182/blood.v98.9.2837] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Chromosomal translocation t(6;14)(p21.1;q32.3) has been reported as a rare but recurrent event not only in myeloma and plasma cell leukemia but also in diffuse large B-cell non-Hodgkin lymphoma (B-NHL) (diffuse large B-cell lymphoma [DLBCL]) and splenic lymphoma with villous lymphocytes (SLVL); however, the nature of the target gene(s) has not been determined. This study identified t(6;14)(p21.1;q32.3) in 3 cases of transformed extranodal marginal zone B-NHL, in 1 case of SLVL, and in 1 case of a low-grade B-cell lymphoproliferative disorder. In a sixth case, a CD5(+) DLBCL, the translocation was identified by molecular cloning in the absence of cytogenetically detectable change. Two chromosomal translocation breakpoints were cloned by using long-distance inverse polymerase chain reaction methods. Comparison with the genomic sequence for chromosome 6p21.1 showed breakpoints approximately 59 and 73.5 kilobases 5' of the cyclin D3 (CCND3) gene with no other identifiable transcribed sequences in the intervening region. Although Southern blotting with derived genomic 6p21.1 probes failed to detect other rearrangements, fluorescent in situ hybridization assays, using BAC (bacterial artificial chromosome) clones spanning and flanking the CCND3 locus, along with probes for IGH confirmed localization of 6p21.1 breakpoints within the same region, as well as fusion of the CCND3 and IGH loci. Furthermore, in all cases, high-level expression of CCND3 was demonstrated at RNA and/or protein levels by Northern and Western blotting and by immunohistochemistry. These data implicate CCND3 as a dominant oncogene in the pathogenesis and transformation in several histologic subtypes of mature B-cell malignancies with t(6;14)(p21.1;q32.3) and suggest that CCND3 overexpression seen in about 10% of DLBCL cases may have a genetic basis.
Collapse
MESH Headings
- Adult
- Aged
- B-Lymphocytes/chemistry
- B-Lymphocytes/pathology
- B-Lymphocytes/ultrastructure
- Base Sequence
- Chromosome Breakage/genetics
- Chromosomes, Human, Pair 14
- Chromosomes, Human, Pair 6
- Cloning, Molecular
- Cyclin D3
- Cyclins/genetics
- Female
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Lymphoma, B-Cell/chemistry
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/pathology
- Lymphoproliferative Disorders/genetics
- Lymphoproliferative Disorders/pathology
- Male
- Middle Aged
- Molecular Sequence Data
- Translocation, Genetic/genetics
Collapse
Affiliation(s)
- T Sonoki
- Academic Department of Haematology and Cytogenetics, Institute of Cancer Research, Sutton, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Lloveras E, Lecumberri JM, Pérez C, Melero C, Zamora L, Sánchez MA, Solé F, Plaja A. A female infant with a 46,XX/48,XY, +8, +10 karyotype in prenatal diagnosis: a 'vanishing twin' phenomenon? Prenat Diagn 2001; 21:896-7. [PMID: 11746139 DOI: 10.1002/pd.174] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
32
|
Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernández JM, Santoja C, Solé F, Sánchez-Beato M, Piris MA. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 2001; 25:1268-76. [PMID: 11688461 DOI: 10.1097/00000478-200110000-00007] [Citation(s) in RCA: 118] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Splenic marginal zone lymphoma (SMZL) is considered to be an indolent extranodal B-cell lymphoma. Despite its low aggressivity, histologic progression has been described in sporadic reports, although the frequency, characteristics, and underlying molecular abnormalities of this phenomenon are largely unknown. We review here the clinical, morphologic, immunohistochemical, and molecular features of a series of 12 SMZL cases that showed progression to large B-cell lymphoma (LBCL). The most frequent location of secondary LBCL was in peripheral lymph node. This occurred between 12 and 85 months after diagnosis of SMZL. However, in two cases LBCL was diagnosed at the initial stage of the disease (one spleen tumoral nodule and one hilar lymph node). The histologic and immunophenotypic features of these cases were similar to those of transformed LBCL at other sites. In four cases the immunoglobulin heavy chain gene polymerase chain study revealed the same rearrangement pattern in both primary and secondary tumors, thereby confirming their identity and excluding the possibility of a second malignancy. As is the case with other low-grade lymphoproliferative disorders, SMZL may undergo high-grade transformation. These 12 cases represent 13% of our series of SMZL with adequate follow-up. The incidence of large cell transformation in SMZL seems to be lower than in follicular lymphoma (25-60%) and mantle cell lymphoma (11-39%), although it is similar to the frequency of transformation in B-chronic lymphocytic lymphoma/small lymphocytic lymphoma (1-10%). The mean proliferative index (MIB1 staining) in initial SMZL specimens of cases with LBCL transformation was 28.6%, higher than that of MIB1 staining in the overall SMZL series (21.8%), although not statistically significantly so. p53 or p16INK4a inactivation in this series was observed in only one case, in contrast with the situation observed in chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma. It seems that progression in SMZL is mainly independent of p53 or p16INK4a inactivation. The frequency of the 7q deletion in this series was 3 of 7 (42%). 7q loss may play an alternative role in the inactivation of the p53 and p16INK4a pathway, thereby favoring tumoral progression.
Collapse
MESH Headings
- Adult
- Aged
- Alleles
- Antigens, Nuclear
- Biomarkers, Tumor/analysis
- Chromosome Deletion
- Chromosomes, Human, Pair 7
- Cyclin-Dependent Kinase Inhibitor p16/analysis
- Cyclin-Dependent Kinase Inhibitor p16/genetics
- DNA Mutational Analysis
- DNA, Neoplasm/analysis
- DNA-Binding Proteins/analysis
- DNA-Binding Proteins/genetics
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Immunohistochemistry
- Immunophenotyping
- Lymphoma, B-Cell/chemistry
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/mortality
- Lymphoma, B-Cell/pathology
- Lymphoma, Large B-Cell, Diffuse/chemistry
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Middle Aged
- Nuclear Proteins/analysis
- Proto-Oncogene Proteins/analysis
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins c-bcl-6
- Splenic Neoplasms/chemistry
- Splenic Neoplasms/genetics
- Splenic Neoplasms/mortality
- Splenic Neoplasms/pathology
- Survival Rate
- Transcription Factors/analysis
- Transcription Factors/genetics
- Tumor Suppressor Protein p53/analysis
- Tumor Suppressor Protein p53/genetics
Collapse
Affiliation(s)
- F I Camacho
- Molecular Pathology Program, Fundación Centro Nacional de Investigaciones Oncológicas Carlos III-CNIO, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Sanchez-Izquierdo D, Siebert R, Harder L, Marugan I, Gozzetti A, Price HP, Gesk S, Hernandez-Rivas JM, Benet I, Solé F, Sonoki T, Le Beau MM, Schlegelberger B, Dyer MJ, Garcia-Conde J, Martinez-Climent JA. Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization. Leukemia 2001; 15:1475-84. [PMID: 11516111 DOI: 10.1038/sj.leu.2402207] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Structural alterations in 3q27 affecting the BCL6 locus are among the most frequent changes in B-NHL. The aim of the present study was to establish an interphase-FISH assay for the detection of all diverse BCL6 translocations in B-NHL. Two different approaches were tested, one using a PAC-clone spanning the major breakpoint region (MBR) of BCL6 (span-assay), and another using two BAC clones flanking the MBR (flank-assay). Interphase FISH with the span-assay detected the various BCL6 translocations in seven B-NHL cell lines. The dual-color flank-assay was evaluated in two laboratories independently: in normal controls, the cutoff level for false-positive signals was 2.6%, whereas the cutoff level for false-negatives in the seven cell lines was 7.5%. To test the feasibility of the FISH strategies, 30 samples from patients with B-NHL with cytogenetic abnormalities of 3q27 were evaluated with both assays. In 21 cases, the span-assay indicated a BCL6 rearrangement. In 18 of the 21 cases, the dual-color flank-assay confirmed the translocation including 12 different partner chromosomal loci. The three false-positive cases detected with the span-assay showed trisomy of chromosome 3 by cytogenetic analyses, and they were correctly classified as non-rearranged with the flank-assay. In summary, our FISH strategy using two differently labeled flanking BCL6 BAC probes provides a robust, sensitive, and reproducible method for the detection of common and uncommon abnormalities of BCL6 gene in interphase nuclei. The routine application of this assay to patients with B-NHL will allow the assessment of the diagnostic and prognostic significance of BCL6 rearrangements.
Collapse
Affiliation(s)
- D Sanchez-Izquierdo
- Department of Hematology and Oncology, Hospital Clinico, University of Valencia, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Hernández JA, Florensa L, Solé F, Bosch MA, Espinet B. Acute myeloid leukemia with 17p abnormality in untreated essential thrombocythemia. Leukemia 2001; 15:1308. [PMID: 11480578 DOI: 10.1038/sj.leu.2402176] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
35
|
Salido M, Solé F, Espinet B, Zamora L, Woessner S, Florensa L. New t(11;12)(q12;q11) characterized by RxFISH in a patient with T-cell large granular lymphocyte leukemia. Cancer Genet Cytogenet 2001; 125:70-3. [PMID: 11297771 DOI: 10.1016/s0165-4608(00)00357-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Chromosomal abnormalities in patients with large granular lymphocyte leukemia (LGLL) are rare. Herein we present a novel cytogenetic abnormality t(11;12)(q12;q11) in a patient with LGLL identified by cross-species color banding (RxFISH). The application of RxFISH allowed the rapid and easy identification of a chromosome rearrangement that was not recognized by conventional cytogenetics. Therefore, RxFISH is a suitable complement to, but not a replacement for, conventional cytogenetics.
Collapse
Affiliation(s)
- M Salido
- Laboratori de Citologia Hematològica/Laboratori de Referència de Catalunya, Unitat d'Hematologia 1973, Hospital del Mar, IMAS, IMIM, Barcelona, Spain.
| | | | | | | | | | | |
Collapse
|
36
|
Solé F, Salido M, Espinet B, Garcia JL, Martinez Climent JA, Granada I, Hernández JM, Benet I, Piris MA, Mollejo M, Martinez P, Vallespí T, Domingo A, Serrano S, Woessner S, Florensa L. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica 2001; 86:71-7. [PMID: 11146574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Splenic marginal zone B-cell lymphoma (SMZBCL) has clinical, immunophenotypic and histologic features distinct from other B-cell malignancies, but few chromosome studies have been previously reported. In the present study we performed conventional cytogenetics and in situ hybridization studies in 47 patients with SMZBCL. DESIGN AND METHODS We studied 47 cases of splenic marginal zone B-cell lymphoma combining conventional cytogenetics and in situ hybridization (ISH) techniques using centromeric probes (chromosomes 3 and 12), locus specific probes (7q31 and 17p13) and cross-species color banding fluorescent ISH probes (RxFISH). The diagnosis of SMZBCL was ascertained in all cases after studying, morphologically and immunologically, peripheral blood and splenectomy specimens. RESULTS A clonal chromosome abnormality detected by conventional cytogenetics and/or FISH was found in 33/47 patients (70%) being identified in 18 (18/33, 55%) as a complex abnormality. The most frequently recurrent abnormalities were: gain of 3q (10 cases), del(7q) (12 cases), and involvement of chromosomes 1, 8 and 14. No patient showed translocation t(11;14) (q13;q32) or t(14;18) (q21;q32). Trisomy 3 was detected in eight cases (8/47, 17%). Two novel cytogenetic abnormalities involving 14q32, t(6;14)(p12;q32) and t(10;14) (q24;q32) were reported. Deletion of 17p13 (P53) was observed by FISH in one case. Only one patient showed a gain of 3q or trisomy 3 and deletion 7q in the same karyotype. INTERPRETATION AND CONCLUSIONS Our findings support the interpretation that two forms of SMZBCL could be considered, one with gain of 3q and the other with deletions at 7q.
Collapse
Affiliation(s)
- F Solé
- Laboratori de Citologia Hematològica, Laboratori de Referència de Catalunya, Departament de Patologia, Hospital del Mar, IMAS, IMIM, Passeig Maritim, 25-29, 08003 Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Espinet B, Solé F, Lloveras E, Abella E, Besses C, Woessner S, Florensa L. Dicentric (17;18) in a case of atypical B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2000; 121:194-7. [PMID: 11063807 DOI: 10.1016/s0165-4608(00)00255-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We report a new dic(17;18)(p11.2;p11.2) in a 61-year-old male patient diagnosed with atypical B-cell chronic lymphocytic leukemia. The dic(17;18)(p11.2;p11.2) was detected in 90%, 10%, and 100% of metaphases in the peripheral blood, bone marrow, and lymph node, respectively. Fluorescence in situ hybridization studies with chromosome 17 and 18 centromeric probes revealed the presence of two normal centromeres of both chromosomes 17 and 18. The centromere of one chromosome 17 was found together with the centromere of one chromosome 18, confirming the dicentric nature of the rearrangement. In addition, with the use of a 17p13.1 region probe, monosomy of the 17p13 region, where the Tp53 gene is located, was observed.
Collapse
Affiliation(s)
- B Espinet
- Laboratori de Citologia Hematològica/Laboratori de Referència de Catalunya, Unitat d'Hematologia 1973, Hospital del Mar, IMAS, IMIM, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
38
|
Lloveras E, Solé F, Espinet B, Besses C, Asensio A, Abella E, Woessner S, Florensa L. Cytogenetic and fluorescence in situ hybridization studies in four cases of plasma cell leukemia. Cancer Genet Cytogenet 2000; 121:163-6. [PMID: 11063801 DOI: 10.1016/s0165-4608(00)00243-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We present a cytogenetic and fluorescence in situ hybridization (FISH) study, using centromeric probes for chromosomes 3, 7, 11, and 18, TP53 gene (17p13), and RB-1 locus (13q14) DNA probes, in four cases of plasma cell leukemia (PCL). Among the four cases, three presented monosomy of the RB-1 locus and one monoallelic deletion of the TP53 gene. The present report shows the usefulness of the FISH technique to detect abnormalities not previously observed by conventional cytogenetics.
Collapse
Affiliation(s)
- E Lloveras
- Laboratori de Citologia Hematològica/Laboratori de Referència de Catalunya, Unitat d'Hematologia, Hospital del Mar, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Manteiga R, Florensa L, Solé F, Prat M, Besses C, Woessner S. CD3(-) large granular lymphocyte leukemia with clonal rearrangement of the gamma and beta genes of the T-cell receptor. Haematologica 2000; 85:879-80. [PMID: 10942944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
MESH Headings
- Antigens, Neoplasm/analysis
- CD3 Complex/analysis
- Cell Differentiation
- Cell Lineage
- Clone Cells/chemistry
- Clone Cells/pathology
- Female
- Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
- Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
- Humans
- Leukemia, Lymphoid/classification
- Leukemia, Lymphoid/genetics
- Leukemia, Lymphoid/pathology
- Middle Aged
- Neoplastic Stem Cells/chemistry
- Neoplastic Stem Cells/pathology
- Receptors, Antigen, T-Cell, alpha-beta/genetics
- Receptors, Antigen, T-Cell, gamma-delta/genetics
- T-Lymphocytes/chemistry
- T-Lymphocytes/pathology
Collapse
|
40
|
Solé F, Espinet B, Salido M, Lloveras E, Fernández C, Cigudosa JC, Asensio A, Woessner S, Florensa L. Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes. Br J Haematol 2000; 110:241-3. [PMID: 10931012 DOI: 10.1046/j.1365-2141.2000.02072-7.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
41
|
Pérez-Vila MF, Espinet B, Solé F, Pedro C, Woessner S, Florensa L. A new case of Sézary cell leukemia: a morphological variant of prolymphocytic leukemia. Haematologica 2000; 85:775-6. [PMID: 10897140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
|
42
|
Espinet B, Solé F, Salido M, Lloveras E, Abella E, Besses C, Serrano S, Woessner S, Florensa L. Application of cross-species color banding (RxFISH) in the study of T-prolymphocytic leukemia. Haematologica 2000; 85:607-12. [PMID: 10870117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Cross-species color banding (RxFISH) is a new FISH technology based on the use of differentially labeled gibbon chromosome probes to obtain a specific color banding pattern for each human chromosome. The aim of the study was to test the RxFISH technique for better characterization of complex karyotypes in patients with T-prolymphocytic leukemia (T-PLL). DESIGN AND METHODS The study evaluated the cross-species color banding technique in four patients affected with T-PLL previously studied by conventional cytogenetics. RESULTS All patients showed an abnormal karyotype and three of them had a complex karyotype. The involvement of 14q11 in all four cases, the gain of 8q in three cases and a loss of chromosome 10, 15 and 17 and a gain of chromosome 21 in two cases were noted. The RxFISH technique identified from 2 to 7 not previously recognized aberrations per case and confirmed the inv(14)(q11q32). INTERPRETATION AND CONCLUSIONS To our knowledge, this is the first application of RxFISH to characterize chromosomal rearrangements in T-cell neoplasms. RxFISH gave rapid and easy identification of chromosome rearrangements that were difficult to recognize by conventional cytogenetics. Using this new technology we identified 15 rearrangements not detected by conventional cytogenetics.
Collapse
Affiliation(s)
- B Espinet
- Laboratori de Citologia Hematològica, Laboratori de Referència de Catalunya, Unitat d'Hematologia 1973, Barcelona, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Espinet B, Florensa L, Solé F, Lloveras E, Abella E, Besses C, Sans-Sabrafen J, Woessner S. Isochromosome +i(3)(q10) in a new case of persistent polyclonal B-cell lymphocytosis (PPBL). Eur J Haematol 2000; 64:344-6. [PMID: 10863981 DOI: 10.1034/j.1600-0609.2000.9l053.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
44
|
Vall Combelles O, Solé F, Bonet Alcaina M, Lloveras E, García Algar O. [Klinefelter 48 XXYY syndrome. Case report]. An Esp Pediatr 2000; 52:483-4. [PMID: 11203413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
45
|
Abstract
A 62-year-old woman with phenotypic stigmata of Turner syndrome and a mosaic cytogenetic pattern, 45,X/45,XX, developed multiple myeloma. The affected cells had a number of karyotypic changes in addition to the loss of the X chromosome.
Collapse
Affiliation(s)
- E L Caballé
- Laboratori de Citologia Hematològica, Hospital de l'Esperança, Barcelona, Spain
| | | | | | | | | |
Collapse
|
46
|
Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, Prieto F, Granada I, Hernández JM, Cigudosa JC, Diez JL, Bureo E, Marqués ML, Arranz E, Ríos R, Martínez Climent JA, Vallespí T, Florensa L, Woessner S. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. Br J Haematol 2000; 108:346-56. [PMID: 10691865 DOI: 10.1046/j.1365-2141.2000.01868.x] [Citation(s) in RCA: 182] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Recently, a consensus International Prognostic Scoring System (IPSS) for predicting outcome and planning therapy in the myelodysplastic syndromes (MDS) has been developed. However, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities for which real prognosis at present is uncertain. The main aims of this study were to evaluate in an independent series the prognostic value of the IPSS and to identify chromosomal abnormalities with a previously unrecognized good or poor prognosis in 640 patients. In univariate analyses, cases with single 1q abnormalities experienced poor survival, whereas those with trisomy 8 had a higher risk of acute leukaemic transformation than the remaining patients (P = 0.004 and P = 0.009 respectively). Patients with single del(12p) had a similar survival to patients with a normal karyotype and showed some trend for a better survival than other cases belonging to the IPSS intermediate-risk cytogenetic subgroup (P = 0.045). Multivariate analyses demonstrated that IPSS cytogenetic prognostic subgroup, proportion of bone marrow blasts and haemoglobin level were the main prognostic factors for survival, and the first two characteristics and platelet count were the best predictors of acute leukaemic transformation risk. A large international co-operative study should be carried out to clarify these findings.
Collapse
Affiliation(s)
- F Solé
- Hospital de l'Esperança/Hospital del Mar/Hospital Central l'Aliança (Barcelona), Hospital la Fé (Valencia), Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Solé F, Florensa L, Espinet B, Besses C, Lloveras E, Woessner S. Absence of bcr/abl rearrangement in 41 patients with essential thrombocythemia. Haematologica 2000; 85:214-5. [PMID: 10681735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
|
48
|
Vall Combelles O, Solé F, Bonet Alcaina M, Lloveras E, García Algar O. Un caso de síndrome de Klinefelter 48 XXYY. An Pediatr (Barc) 2000. [DOI: 10.1016/s1695-4033(00)77386-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
49
|
Espinet B, Lloveras E, Solé F. [In situ hybridization techniques. Basis and applications in hematologic neoplasias]. Sangre (Barc) 1999; 44:261-7. [PMID: 10589277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Affiliation(s)
- B Espinet
- Laboratori de Citologia Hematològica, LRC, Hospital de l'Esperança-Hospital del Mar, Barcelona
| | | | | |
Collapse
|
50
|
Ortega M, Coll MD, Solé F, Caballín MR. [Minimal residual disease. Methodologies and clinical implications]. Sangre (Barc) 1999; 44:283-90. [PMID: 10589280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Affiliation(s)
- M Ortega
- Departamento de Biología Animal, Biología Vegetal y Ecología, Facultad de Ciencias, Universidad Autónoma de Barcelona
| | | | | | | |
Collapse
|